Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age

NCT07117487 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07117487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07117487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2025
Completion date
March 27, 2026
Enrollment
507 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus